For Research Use Only. Everything on this site is intended solely for laboratory, analytical, or institutional research — not for human or veterinary use, consumption, diagnosis, treatment, or prevention.

Comparison & documentation

CJC-1295 vs. Ipamorelin

Two of the most frequently paired peptides in research catalogs — here's how they differ in classification and structure, and what to check on the documentation for each.

The short answer

Different receptor classes, commonly studied together.

CJC-1295 is a growth-hormone-releasing hormone (GHRH) analog. Ipamorelin is a ghrelin-receptor-agonist peptide, a class often called a growth-hormone secretagogue. They are structurally distinct compounds acting through different receptor pathways — which is the reason they show up together in research contexts so often.

Classification comparison

AttributeCJC-1295Ipamorelin
ClassificationGHRH analogGhrelin-receptor agonist (GH secretagogue)
Receptor pathwayGHRH receptorGrowth hormone secretagogue receptor (GHS-R)
Common labeled formLyophilized powderLyophilized powder
DAAVY listingSold as one combined vial — CJC-1295 + Ipamorelin, 5 mg + 5 mg, documented under COA7573

Why they're commonly paired in research

CJC-1295 and Ipamorelin are structurally distinct peptides in different pharmacological classes — a GHRH analog and a ghrelin-receptor agonist, respectively. DAAVY Research supplies them as a single combined vial rather than two separate SKUs; this is a catalog and documentation format, not a statement about combined use or outcomes.

Reading the documentation for a combined listing

For a combined vial, the COA should clearly identify both components and their respective labeled amounts (5 mg each, in this case). See our full COA guide for the general checklist, and our HPLC vs. LC-MS guide for what the stated test method actually tells you about either compound.

Frequently asked questions

Are CJC-1295 and Ipamorelin the same class of compound?

No. CJC-1295 is a GHRH analog; Ipamorelin is a ghrelin-receptor-agonist peptide. They act on different receptor pathways.

Why does DAAVY Research sell them as one combined listing?

DAAVY Research supplies them as a single combined vial (5 mg + 5 mg) rather than two separate products; this is a catalog format decision, not a statement about combined use.

Does one COA cover both compounds?

Yes — COA7573 documents the combined product as sold. Review it directly to see what was tested.